"Rifampin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)
| Descriptor ID |
D012293
|
| MeSH Number(s) |
D03.633.400.811.700 D04.345.295.750.700
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Rifampin".
Below are MeSH descriptors whose meaning is more specific than "Rifampin".
This graph shows the total number of publications written about "Rifampin" by people in this website by year, and whether "Rifampin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 |
| 2006 | 1 | 0 | 1 |
| 2008 | 2 | 1 | 3 |
| 2009 | 1 | 0 | 1 |
| 2010 | 1 | 1 | 2 |
| 2011 | 3 | 2 | 5 |
| 2012 | 2 | 2 | 4 |
| 2013 | 1 | 1 | 2 |
| 2014 | 0 | 2 | 2 |
| 2015 | 4 | 3 | 7 |
| 2016 | 6 | 2 | 8 |
| 2017 | 4 | 3 | 7 |
| 2018 | 6 | 3 | 9 |
| 2019 | 5 | 5 | 10 |
| 2020 | 1 | 4 | 5 |
| 2021 | 4 | 13 | 17 |
| 2022 | 0 | 9 | 9 |
| 2023 | 0 | 8 | 8 |
| 2024 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Rifampin" by people in Profiles.
-
Accuracy of cobas MTB and MTB-RIF/INH for Detection of Mycobacterium tuberculosis and Drug Resistance. J Mol Diagn. 2024 Aug; 26(8):708-718.
-
Target regimen profiles for tuberculosis treatment. Bull World Health Organ. 2024 Aug 01; 102(8):600-607.
-
Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial. Lancet Infect Dis. 2024 Sep; 24(9):1003-1014.
-
Organisation of care for people receiving drug-resistant tuberculosis treatment in South Africa: a mixed methods study. BMJ Open. 2023 11 17; 13(11):e067121.
-
Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial. Lancet Respir Med. 2024 Feb; 12(2):117-128.
-
1-Year Incidence of Tuberculosis Infection and Disease Among Household Contacts of Rifampin- and Multidrug-Resistant Tuberculosis. Clin Infect Dis. 2023 09 18; 77(6):892-900.
-
Children deserve simple, short, safe, and effective treatment for rifampicin-resistant tuberculosis. Lancet Infect Dis. 2023 07; 23(7):778-780.
-
Completion, safety, and efficacy of tuberculosis preventive treatment regimens containing rifampicin or rifapentine: an individual patient data network meta-analysis. Lancet Respir Med. 2023 09; 11(9):782-790.
-
Factors associated with prevalent Mycobacterium tuberculosis infection and disease among adolescents and adults exposed to rifampin-resistant tuberculosis in the household. PLoS One. 2023; 18(3):e0283290.
-
Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349). Clin Infect Dis. 2023 02 08; 76(3):e580-e589.